Category Archive for "Research"

Home »

Why ABBV is Still a Value

GILD’s disclosure of an expected 46% average Harvoni discount for 2015 reduces our net pricing expectations for ABBV’s Viekira Pak to roughly $42,000 per regimen, down from roughly $60,000 Despite this, we still see ABBV as a value, simply because

Read More

Advertising: The “Golden Age” of TV Enters its Golden Years

US TV advertising has crested and is beginning its inevitable decline. In an era of rising transmission fees and a vigorous market for content licensing, media companies have been reporting disappointing revenues for their TV network units – the result

Read More

Quick Thoughts: AMZN and GOOG – Looking for Some Investor Love

–       AMZN jumped nearly 9% after hours after turning in a surprise $0.45/share profit, while GOOG held serve on a nominal miss caused by a 4% YoY FX hit and a few one-time items. –       AMZN was typically cryptic, but

Read More

DuPont – Trian Engages the Big Gun!

DuPont – Trian Engages the BIG Gun! Trian, today, announced the formation of Trian Advisory Partners, charged with the following: “Trian Advisory Partners will provide support to Trian by identifying potential investment opportunities, assisting with due diligence, formulating strategic and operating

Read More

MCD – The Journey of 1,000 Miles Begins with a Single Step

McDonald’s (MCD) has had a difficult two (plus) year period, and the CEO during that period (Don Thompson) will not be part of any potential recovery as he was replaced last night by the company’s Chief Brand Officer, Steve Easterbrook. 

Read More

Quick Thoughts: FB and QCOM – Beat, Guide and Drop

–       FB and QCOM both beat consensus expectations for Dec Q sales and EPS handily, however rising costs at FB and skittish guidance from QCOM sent both stocks down after hours, QCOM sharply so –       QCOM lost some SoC business

Read More

Quick Thoughts: AAPL – Awesome! Epic! When Should We Sell?

–     AAPL sold 74.4M iPhones in its 1QF15, up 46% YoY and nearly 10M above consensus – with an ASP of $687, up 7.8% YoY – driving sales of $74.6B and EPS of $3.06, both WAY above expectations –     The

Read More

Quick Thoughts: MSFT – Moving Quickly to the Cloud

– MSFT’s 2QF15 beat on both the top and bottom lines. Adjusting for one-time items, EPS was $0.77 ahead of the $0.71 consensus, and sales of $26.47B edged expectations on 7.9% YoY growth. – Businesses central to the “mobile first,

Read More

The Bull Case for SNY’s Diabetes Franchise – Update

Consensus expectations for SNY’s basal insulins (Lantus/Toujeo) appear too low. Expectations fell 28% after SNY warned last October that US pricing had weakened, and have fallen to the point that consensus now expects 2017 sales to be lower than 2014

Read More

Quick Thoughts: MSFT – Mobile First, Cloud First, CHECK!

–     MSFT revealed details on Windows 10 – tight integration btw phones, PCs and Xbox; free upgrade for Windows 7 & 8 users; traditional look but modern functionality; a powerful new browser, etc. –     Free upgrade will drive fast adoption,

Read More
test